Skip to main content
Erschienen in: Annals of Nuclear Medicine 1/2021

22.10.2020 | Original Article

The prognostic role of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: a pilot study application of neural networks to predict time-to-event

verfasst von: Salvatore Annunziata, Armando Pelliccioni, Stefan Hohaus, Elena Maiolo, Annarosa Cuccaro, Alessandro Giordano

Erschienen in: Annals of Nuclear Medicine | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the prognostic role of end-of-treatment (EoT) FDG-PET/CT parameters in diffuse large B cell lymphoma (DLBCL), and then to explore a pilot application of Neural Networks (NN) in predicting time-to-relapse.

Methods

For conventional survival analysis, parameters as Deauville score (DS) and quantitative extension of DS (qPET) were correlated to adverse events as relapse or progression in the follow-up. To build NN and conventional multi-regression models (MM) for time-to-event prediction, patients with residual FDG uptake (DS ≥ 2) and an adverse event were divided into a training and a test group. Models developed on the training group were evaluated in the test group. Pearson correlation coefficient (R) and mean relative error between observed and forecasted time-to-event were calculated.

Results

FDG-PET/CT data of 308 patients with DLBCL were analyzed. DS and qPET were prognostic factors in conventional univariate analysis. Positive and negative predictive values, respectively, were 55% and 83% for DS 4–5, 89% and 82% for positive qPET. Focusing on 37 relapsed patients with a residual FDG uptake, R between observed and forecasted time-to-event was of 0.63 in the NN model and 0.49 in the MM. Mean relative error in predicting time-to-event was of 58% for NN and 67% for MM.

Conclusions

EoT FDG-PET/CT visual score (DS) is a strong outcome predictor in DLBCL in a large monocentric cohort. The semi-quantitative parameter qPET may increase this prognostic performance. A pilot NN model applied on residual FDG uptake parameters seems to predict time-to-event in the follow-up.
Literatur
1.
Zurück zum Zitat Hüttmann A, Rekowski J, Müller SP, et al. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas” (PETAL) trial. Ann Hematol. 2019;98:897–907. CrossRef Hüttmann A, Rekowski J, Müller SP, et al. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas” (PETAL) trial. Ann Hematol. 2019;98:897–907. CrossRef
2.
Zurück zum Zitat Toledano MN, Vera P, Tilly H, et al. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: prognostic impact of tumor/liver ratio. PLoS ONE. 2019;14:e0211649. CrossRef Toledano MN, Vera P, Tilly H, et al. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: prognostic impact of tumor/liver ratio. PLoS ONE. 2019;14:e0211649. CrossRef
3.
Zurück zum Zitat Zhang Y, Fan Y, Ying Z, et al. Can the SUV(max-liver)-based interpretation improve prognostic accuracy of interim and posttreatment (18)F-FDG PET/CT in patients with diffuse large B-cell lymphoma? Leuk Lymphoma. 2018;59:660–9. CrossRef Zhang Y, Fan Y, Ying Z, et al. Can the SUV(max-liver)-based interpretation improve prognostic accuracy of interim and posttreatment (18)F-FDG PET/CT in patients with diffuse large B-cell lymphoma? Leuk Lymphoma. 2018;59:660–9. CrossRef
4.
Zurück zum Zitat Hasenclever D, Kurch L, Mauz-Körholz C, et al. qPET—a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1301–8. CrossRef Hasenclever D, Kurch L, Mauz-Körholz C, et al. qPET—a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1301–8. CrossRef
5.
Zurück zum Zitat Annunziata S, Cuccaro A, Calcagni ML, et al. Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). Ann Nucl Med. 2016;30:588–92. CrossRef Annunziata S, Cuccaro A, Calcagni ML, et al. Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). Ann Nucl Med. 2016;30:588–92. CrossRef
6.
Zurück zum Zitat Annunziata S, Cuccaro A, Tisi MC, et al. FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUV(max) (rPET). Ann Nucl Med. 2018;32:372–7. CrossRef Annunziata S, Cuccaro A, Tisi MC, et al. FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUV(max) (rPET). Ann Nucl Med. 2018;32:372–7. CrossRef
7.
Zurück zum Zitat Papp L, Spielvogel CP, Rausch I, et al. Personalizing medicine through hybrid imaging and medical big data analysis. Front Phys. 2018;6:51. CrossRef Papp L, Spielvogel CP, Rausch I, et al. Personalizing medicine through hybrid imaging and medical big data analysis. Front Phys. 2018;6:51. CrossRef
8.
Zurück zum Zitat Kourou K, Exarchos TP, Exarchos KP, et al. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8–17. CrossRef Kourou K, Exarchos TP, Exarchos KP, et al. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8–17. CrossRef
10.
Zurück zum Zitat Ripley RM, Harris AL, Tarassenko L. Non-linear survival analysis using neural networks. Stat Med. 2004;23:825–42. CrossRef Ripley RM, Harris AL, Tarassenko L. Non-linear survival analysis using neural networks. Stat Med. 2004;23:825–42. CrossRef
11.
Zurück zum Zitat Chi SQ, Tian Y, Li J, et al. Time-dependent and nonlinear effects of prognostic factors in nonmetastatic colorectal cancer. Cancer Med. 2017;6:1882–92. CrossRef Chi SQ, Tian Y, Li J, et al. Time-dependent and nonlinear effects of prognostic factors in nonmetastatic colorectal cancer. Cancer Med. 2017;6:1882–92. CrossRef
12.
Zurück zum Zitat Kirienko M, Sollini M, Silvestri G, et al. Convolutional neural networks promising in lung cancer T-parameter assessment on baseline FDG-PET/CT. Contrast Media Mol Imaging. 2018;2018:1382309. CrossRef Kirienko M, Sollini M, Silvestri G, et al. Convolutional neural networks promising in lung cancer T-parameter assessment on baseline FDG-PET/CT. Contrast Media Mol Imaging. 2018;2018:1382309. CrossRef
13.
Zurück zum Zitat Papp L, Pötsch N, Grahovac M, et al. Glioma survival prediction with combined analysis of in vivo (11)C-MET PET features, ex vivo features, and patient features by supervised machine learning. J Nucl Med. 2018;59:892–9. CrossRef Papp L, Pötsch N, Grahovac M, et al. Glioma survival prediction with combined analysis of in vivo (11)C-MET PET features, ex vivo features, and patient features by supervised machine learning. J Nucl Med. 2018;59:892–9. CrossRef
14.
Zurück zum Zitat Ypsilantis PP, Siddique M, Sohn HM, et al. Predicting response to neoadjuvant chemotherapy with PET imaging using convolutional neural networks. PLoS ONE. 2015;10:e0137036. CrossRef Ypsilantis PP, Siddique M, Sohn HM, et al. Predicting response to neoadjuvant chemotherapy with PET imaging using convolutional neural networks. PLoS ONE. 2015;10:e0137036. CrossRef
15.
Zurück zum Zitat Zaidi H, Alavi A, Naqa IE. Novel quantitative PET techniques for clinical decision support in oncology. Semin Nucl Med. 2018;48:548–64. CrossRef Zaidi H, Alavi A, Naqa IE. Novel quantitative PET techniques for clinical decision support in oncology. Semin Nucl Med. 2018;48:548–64. CrossRef
16.
Zurück zum Zitat Sharif MS, Abbod M, Amira A, et al. Artificial neural network-based system for PET volume segmentation. Int J Biomed Imag. 2010;2010:1–11. CrossRef Sharif MS, Abbod M, Amira A, et al. Artificial neural network-based system for PET volume segmentation. Int J Biomed Imag. 2010;2010:1–11. CrossRef
17.
Zurück zum Zitat Zhang H, Molitoris J, Tan S, et al. SU-F-R-04: radiomics for survival prediction in glioblastoma (GBM). Med Phys. 2016;43:3373–3373. CrossRef Zhang H, Molitoris J, Tan S, et al. SU-F-R-04: radiomics for survival prediction in glioblastoma (GBM). Med Phys. 2016;43:3373–3373. CrossRef
18.
Zurück zum Zitat Pinnix CC, Ng AK, Dabaja BS, et al. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018;12(2):1334–43. CrossRef Pinnix CC, Ng AK, Dabaja BS, et al. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018;12(2):1334–43. CrossRef
19.
Zurück zum Zitat Strigari L, Attili A, Duggento A, et al. Quantitative analysis of basal and interim PET/CT images for predicting tumor recurrence in patients with Hodgkin’s lymphoma. Nucl Med Commun. 2016;37:16–22. CrossRef Strigari L, Attili A, Duggento A, et al. Quantitative analysis of basal and interim PET/CT images for predicting tumor recurrence in patients with Hodgkin’s lymphoma. Nucl Med Commun. 2016;37:16–22. CrossRef
20.
Zurück zum Zitat Ben Bouallègue F, Tabaa YA, Kafrouni M, et al. Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas. Med Phys. 2017;44:4608–19. CrossRef Ben Bouallègue F, Tabaa YA, Kafrouni M, et al. Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas. Med Phys. 2017;44:4608–19. CrossRef
21.
Zurück zum Zitat Lue KH, Wu YF, Liu SH, et al. Prognostic value of pretreatment radiomic features of 18F-FDG PET in patients with hodgkin lymphoma. Clin Nucl Med. 2019;44:e559–65. CrossRef Lue KH, Wu YF, Liu SH, et al. Prognostic value of pretreatment radiomic features of 18F-FDG PET in patients with hodgkin lymphoma. Clin Nucl Med. 2019;44:e559–65. CrossRef
22.
Zurück zum Zitat Mayerhoefer ME, Riedl CC, Kumar A, et al. Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. Eur J Nucl Med Mol Imaging. 2019;46:2760. CrossRef Mayerhoefer ME, Riedl CC, Kumar A, et al. Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. Eur J Nucl Med Mol Imaging. 2019;46:2760. CrossRef
23.
Zurück zum Zitat Tatsumi M, Isohashi K, Matsunaga K, et al. Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma. Int J Clin Oncol. 2019;24:1292–300. CrossRef Tatsumi M, Isohashi K, Matsunaga K, et al. Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma. Int J Clin Oncol. 2019;24:1292–300. CrossRef
24.
Zurück zum Zitat Milgrom SA, Elhalawani H, Lee J, et al. A PET radiomics model to predict refractory mediastinal Hodgkin lymphoma. Sci Rep. 2019;9:1322. CrossRef Milgrom SA, Elhalawani H, Lee J, et al. A PET radiomics model to predict refractory mediastinal Hodgkin lymphoma. Sci Rep. 2019;9:1322. CrossRef
25.
Zurück zum Zitat Lee JW, Park JY, Lee HJ, et al. Preoperative [(18)F]FDG PET/CT tumour heterogeneity index in patients with uterine leiomyosarcoma: a multicentre retrospective study. Eur J Nucl Med Mol Imaging. 2018;45:1309–16. CrossRef Lee JW, Park JY, Lee HJ, et al. Preoperative [(18)F]FDG PET/CT tumour heterogeneity index in patients with uterine leiomyosarcoma: a multicentre retrospective study. Eur J Nucl Med Mol Imaging. 2018;45:1309–16. CrossRef
26.
Zurück zum Zitat Kim YI, Kim YJ, Paeng JC, et al. Heterogeneity index evaluated by slope of linear regression on (18)F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2017;44:1995–2003. CrossRef Kim YI, Kim YJ, Paeng JC, et al. Heterogeneity index evaluated by slope of linear regression on (18)F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2017;44:1995–2003. CrossRef
Metadaten
Titel
The prognostic role of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: a pilot study application of neural networks to predict time-to-event
verfasst von
Salvatore Annunziata
Armando Pelliccioni
Stefan Hohaus
Elena Maiolo
Annarosa Cuccaro
Alessandro Giordano
Publikationsdatum
22.10.2020
Verlag
Springer Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 1/2021
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-020-01542-y

Weitere Artikel der Ausgabe 1/2021

Annals of Nuclear Medicine 1/2021 Zur Ausgabe